AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
Log in

NASDAQ:CYCCCyclacel Pharmaceuticals Stock Price, Forecast & News

$5.84
+0.48 (+8.96 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.41
Now: $5.84
$5.95
50-Day Range
$0.37
MA: $3.84
$8.64
52-Week Range
$3.85
Now: $5.84
$19.60
Volume1.03 million shs
Average Volume504,156 shs
Market Capitalization$28.38 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Read More
Cyclacel Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCC
CUSIPN/A
Phone908-517-7330

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$13.60 per share

Profitability

Net Income$-7,830,000.00

Miscellaneous

Employees14
Market Cap$28.38 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

How has Cyclacel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYCC stock has increased by 981.7% and is now trading at $5.84. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cyclacel Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cyclacel Pharmaceuticals.

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Cyclacel Pharmaceuticals.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) announced its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported ($1.48) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($2.90) by $1.42. View Cyclacel Pharmaceuticals' earnings history.

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Shares of Cyclacel Pharmaceuticals reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

Has Cyclacel Pharmaceuticals been receiving favorable news coverage?

Media headlines about CYCC stock have been trending negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cyclacel Pharmaceuticals earned a news impact score of -2.6 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutCyclacel Pharmaceuticals.

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 125,400 shares, an increase of 1,040.0% from the April 30th total of 11,000 shares. Based on an average daily trading volume, of 468,900 shares, the days-to-cover ratio is currently 0.3 days. Currently, 15.1% of the shares of the stock are sold short. View Cyclacel Pharmaceuticals' Current Options Chain.

Who are some of Cyclacel Pharmaceuticals' key competitors?

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Novavax (NVAX), McEwen Mining (MUX), NVIDIA (NVDA), Exelixis (EXEL) and Boeing (BA).

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the following people:
  • Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)
  • Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)
  • Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)
  • Ms. Gill Christie, Director of HR (Age 62)
  • Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75)

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $5.84.

How big of a company is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has a market capitalization of $28.38 million and generates $150,000.00 in revenue each year. Cyclacel Pharmaceuticals employs 14 workers across the globe.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is www.cyclacel.com.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.